Index RUT
P/E -
EPS (ttm) -2.96
Insider Own 5.17%
Shs Outstand 84.83M
Perf Week 4.70%
Market Cap 1.87B
Forward P/E -
EPS next Y -2.93
Insider Trans 0.00%
Shs Float 80.57M
Perf Month -2.52%
Income -209.36M
PEG -
EPS next Q -0.98
Inst Own 99.99%
Short Float 11.92%
Perf Quarter 7.09%
Sales 0.00M
P/S -
EPS this Y -29.45%
Inst Trans 7.03%
Short Ratio 8.72
Perf Half Y 58.41%
Book/sh 6.53
P/B 3.38
EPS next Y 24.16%
ROA -37.72%
Short Interest 9.60M
Perf Year 8.19%
Cash/sh 6.72
P/C 3.28
EPS next 5Y -
ROE -40.98%
52W Range 11.22 - 25.34
Perf YTD 2.04%
Dividend Est. -
P/FCF -
EPS past 5Y -0.41%
ROI -37.74%
52W High -12.98%
Beta 1.04
Dividend TTM -
Quick Ratio 10.00
Sales past 5Y 1801.91%
Gross Margin -
52W Low 96.61%
ATR (14) 0.89
Dividend Ex-Date -
Current Ratio 10.00
EPS Y/Y TTM -20.58%
Oper. Margin 0.00%
RSI (14) 52.99
Volatility 4.57% 3.43%
Employees 184
Debt/Eq 0.00
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.23
Target Price 34.92
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -61.13%
Payout -
Rel Volume 0.55
Prev Close 21.86
Sales Surprise -
EPS Surprise -3.26%
Sales Q/Q -
Earnings Feb 27 AMC
Avg Volume 1.10M
Price 22.05
SMA20 2.49%
SMA50 -2.28%
SMA200 15.57%
Trades
Volume 605,285
Change 0.87%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-31-24 Downgrade
Scotiabank
Sector Outperform → Sector Perform
$36 → $23
Dec-22-23 Initiated
Mizuho
Buy
$45
Oct-25-23 Initiated
BofA Securities
Buy
$29
Oct-11-23 Initiated
Goldman
Buy
$30
Jul-27-23 Initiated
Scotiabank
Sector Outperform
Jul-11-23 Initiated
Guggenheim
Buy
$40
Apr-17-23 Resumed
BTIG Research
Buy
$34
Jan-31-23 Initiated
Stifel
Buy
$37
Jan-03-23 Initiated
JP Morgan
Overweight
$41
Jul-28-22 Resumed
B. Riley Securities
Buy
$31
Apr-11-22 Initiated
H.C. Wainwright
Buy
$31
Feb-15-22 Initiated
Goldman
Buy
$37
Jun-04-21 Resumed
Robert W. Baird
Outperform
$30 → $31
May-25-21 Initiated
Citigroup
Buy
$24
Feb-18-21 Initiated
B. Riley Securities
Buy
$30
Dec-03-20 Initiated
Stifel
Buy
$32
May-22-20 Upgrade
Citigroup
Neutral → Buy
$26 → $23
May-22-20 Downgrade
H.C. Wainwright
Buy → Neutral
$25 → $15
May-18-20 Downgrade
Citigroup
Buy → Neutral
May-11-20 Reiterated
H.C. Wainwright
Buy
$19 → $25
Show Previous Ratings
May-03-24 04:05PM
May-01-24 07:00AM
Apr-10-24 04:05PM
Apr-08-24 07:00AM
Apr-05-24 04:05PM
09:54AM
Loading…
Mar-28-24 09:54AM
07:00AM
06:00AM
Mar-26-24 04:05PM
Mar-18-24 07:00AM
Mar-03-24 08:29AM
Mar-01-24 04:05PM
Feb-28-24 01:10PM
(Thomson Reuters StreetEvents)
Feb-27-24 04:47PM
(Associated Press Finance)
04:05PM
08:50AM
Loading…
Feb-26-24 08:50AM
07:00AM
Feb-20-24 04:05PM
Feb-02-24 04:05PM
Feb-01-24 04:10PM
Jan-09-24 01:51PM
Jan-05-24 04:05PM
Jan-02-24 04:05PM
07:00AM
Dec-19-23 04:16PM
Dec-18-23 02:58PM
Dec-14-23 11:07PM
04:00PM
Dec-12-23 12:00PM
Dec-11-23 07:30AM
05:00PM
Loading…
Dec-10-23 05:00PM
Dec-05-23 01:34PM
Dec-04-23 07:00AM
Dec-01-23 04:05PM
Nov-21-23 09:00AM
Nov-07-23 07:00AM
Nov-04-23 12:16PM
Nov-03-23 04:05PM
09:56AM
Nov-02-23 07:29PM
04:52PM
(Associated Press Finance)
04:05PM
09:00AM
09:00AM
Oct-27-23 11:51AM
Oct-26-23 07:00AM
Oct-24-23 07:00AM
Oct-06-23 04:05PM
Oct-02-23 07:00AM
Sep-29-23 04:05PM
Sep-01-23 04:05PM
Aug-31-23 04:05PM
Aug-04-23 04:05PM
Aug-03-23 05:10PM
(Associated Press Finance)
04:05PM
Jul-25-23 07:00AM
Jul-24-23 07:00AM
Jul-07-23 04:05PM
Jun-02-23 04:05PM
May-24-23 07:00AM
May-09-23 09:51AM
(Thomson Reuters StreetEvents) +6.55%
May-08-23 04:55PM
04:05PM
May-01-23 07:00AM
Apr-13-23 04:05PM
Apr-07-23 04:05PM
Apr-05-23 06:00PM
Apr-03-23 06:15PM
Mar-30-23 07:00AM
Mar-27-23 06:15PM
Mar-21-23 06:00PM
Mar-15-23 06:00PM
04:05PM
Mar-14-23 06:15PM
Mar-06-23 04:05PM
01:06AM
Feb-28-23 04:03PM
Feb-24-23 09:00AM
Feb-21-23 06:00PM
07:00AM
Feb-14-23 10:37AM
07:00AM
Feb-13-23 06:00PM
Feb-09-23 01:35PM
Feb-08-23 09:00AM
Feb-07-23 06:00PM
Feb-06-23 08:50AM
Feb-01-23 06:00PM
Jan-23-23 06:00PM
07:40AM
Jan-20-23 08:50AM
07:34AM
Jan-19-23 10:26AM
Jan-18-23 12:00PM
Jan-17-23 06:15PM
09:36AM
Jan-16-23 09:40AM
Jan-11-23 06:15PM
09:38AM
Jan-10-23 01:16PM
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Morrison Briggs Director Aug 09 '23 Option Exercise 8.77 52,855 463,538 70,691 Aug 10 06:50 AM Morrison Briggs Director Aug 09 '23 Sale 18.27 52,855 965,402 17,836 Aug 10 06:50 AM Meury William Director Aug 02 '23 Option Exercise 8.02 83,000 665,250 83,000 Aug 03 09:12 AM Meury William Director Aug 02 '23 Sale 20.46 83,000 1,697,810 48,000 Aug 03 09:12 AM Morrison Briggs Director Jul 10 '23 Option Exercise 8.77 52,855 463,538 70,691 Jul 11 09:23 AM Morrison Briggs Director Jul 10 '23 Sale 20.40 52,855 1,078,068 17,836 Jul 11 09:23 AM Goldan Keith A. Chief Financial Officer Jun 13 '23 Sale 22.31 577 12,873 2,628 Jun 14 04:20 PM Morrison Briggs Director Jun 09 '23 Option Exercise 7.66 52,855 404,787 70,691 Jun 09 05:32 PM Morrison Briggs Director Jun 09 '23 Sale 21.18 52,855 1,119,421 17,836 Jun 09 05:32 PM Morrison Briggs Director May 09 '23 Option Exercise 6.38 52,855 337,215 70,691 May 10 04:11 PM Morrison Briggs Director May 09 '23 Sale 21.41 52,855 1,131,478 17,836 May 10 04:11 PM
Index -
P/E -
EPS (ttm) -4.46
Insider Own 1.19%
Shs Outstand 42.43M
Perf Week 8.14%
Market Cap 1.05B
Forward P/E -
EPS next Y -5.08
Insider Trans -5.07%
Shs Float 42.13M
Perf Month 8.71%
Income -168.42M
PEG -
EPS next Q -1.14
Inst Own 86.92%
Short Float 7.03%
Perf Quarter 45.36%
Sales 41.65M
P/S 25.16
EPS this Y 12.57%
Inst Trans 2.12%
Short Ratio 7.40
Perf Half Y 60.13%
Book/sh 8.35
P/B 2.94
EPS next Y -14.44%
ROA -34.51%
Short Interest 2.96M
Perf Year 12.60%
Cash/sh 10.72
P/C 2.29
EPS next 5Y -
ROE -56.21%
52W Range 12.54 - 28.91
Perf YTD 35.95%
Dividend Est. -
P/FCF -
EPS past 5Y -12.36%
ROI -42.65%
52W High -14.98%
Beta 0.90
Dividend TTM -
Quick Ratio 10.42
Sales past 5Y 38.55%
Gross Margin 84.02%
52W Low 96.01%
ATR (14) 1.29
Dividend Ex-Date -
Current Ratio 10.42
EPS Y/Y TTM -6.85%
Oper. Margin -511.65%
RSI (14) 59.75
Volatility 6.06% 5.00%
Employees 284
Debt/Eq 0.12
Sales Y/Y TTM 168.66%
Profit Margin -404.37%
Recom 1.25
Target Price 43.20
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q 52.52%
Payout -
Rel Volume 0.67
Prev Close 24.69
Sales Surprise 222.11%
EPS Surprise 50.44%
Sales Q/Q 295.08%
Earnings May 02 BMO
Avg Volume 399.79K
Price 24.58
SMA20 7.11%
SMA50 2.38%
SMA200 21.16%
Trades
Volume 267,041
Change -0.45%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-11-23 Upgrade
B. Riley Securities
Neutral → Buy
Aug-31-22 Initiated
Cowen
Outperform
Jul-28-22 Initiated
Barclays
Overweight
$30
Jul-06-22 Resumed
Canaccord Genuity
Buy
$60
Apr-13-22 Downgrade
B. Riley Securities
Buy → Neutral
$62 → $33
Apr-07-22 Resumed
Cantor Fitzgerald
Overweight
$100 → $80
Feb-14-22 Initiated
Morgan Stanley
Equal-Weight
$60
Dec-17-21 Initiated
SVB Leerink
Outperform
$70
Dec-09-21 Initiated
Needham
Buy
$85
Sep-30-21 Initiated
B. Riley Securities
Buy
$56
Apr-20-21 Initiated
JMP Securities
Mkt Outperform
$53
Oct-12-20 Initiated
Cantor Fitzgerald
Overweight
$30
Jun-12-20 Initiated
Oppenheimer
Outperform
Apr-17-20 Initiated
H.C. Wainwright
Buy
$25
Nov-14-19 Initiated
ROTH Capital
Buy
$17
Sep-11-19 Upgrade
Goldman
Neutral → Buy
$14
Jun-17-19 Initiated
Piper Jaffray
Overweight
$20
Jun-17-19 Initiated
Jefferies
Buy
$22
Jun-17-19 Initiated
Goldman
Neutral
$14
Jun-17-19 Initiated
Canaccord Genuity
Buy
$22
Show Previous Ratings
May-02-24 01:54PM
08:44AM
07:00AM
Apr-24-24 10:05AM
Apr-02-24 07:00AM
04:35PM
Loading…
Mar-05-24 04:35PM
Feb-28-24 07:00AM
Feb-20-24 07:05AM
Feb-07-24 07:00AM
Jan-22-24 10:54AM
Jan-05-24 02:02AM
Dec-14-23 07:00AM
Nov-30-23 07:00AM
Nov-02-23 08:46AM
07:00AM
06:04AM
Loading…
06:04AM
Oct-30-23 07:00AM
Oct-19-23 07:00AM
04:00AM
Sep-14-23 10:12AM
Sep-12-23 07:54AM
06:36AM
Sep-11-23 02:19PM
07:00AM
Sep-05-23 07:00AM
Aug-03-23 06:59AM
Jul-18-23 07:00AM
06:45AM
Jul-14-23 06:47AM
Jul-13-23 06:40PM
10:23PM
Loading…
Jul-12-23 10:23PM
04:01PM
Jun-23-23 07:30AM
Jun-13-23 07:00AM
May-31-23 07:00AM
May-14-23 08:05AM
May-11-23 06:59AM
May-10-23 08:00AM
07:29AM
May-04-23 09:55AM
07:00AM
06:45AM
Apr-14-23 07:00AM
Apr-03-23 07:00AM
Mar-31-23 06:36AM
Mar-29-23 08:17AM
Mar-28-23 07:00AM
Feb-28-23 09:00AM
07:00AM
Feb-14-23 06:59AM
Feb-08-23 07:00AM
Jan-29-23 09:46AM
Jan-11-23 07:00AM
Jan-04-23 07:00AM
Nov-10-22 09:09AM
Nov-09-22 08:03AM
Nov-08-22 07:00AM
05:03AM
Nov-04-22 07:00AM
Nov-03-22 07:00AM
Oct-10-22 07:00AM
Sep-19-22 04:05PM
Sep-07-22 07:00AM
Sep-06-22 07:00AM
Aug-24-22 07:48PM
Aug-04-22 06:59AM
Aug-02-22 04:05PM
Jul-12-22 04:05PM
07:00AM
Jun-30-22 08:39AM
Jun-08-22 07:00AM
Jun-01-22 07:00AM
May-26-22 05:00PM
May-16-22 07:03AM
May-05-22 06:59AM
Apr-20-22 09:17AM
Apr-11-22 11:57AM
07:44AM
07:41AM
07:00AM
Apr-08-22 04:07PM
(Investor's Business Daily) +24.54%
03:02PM
01:00PM
Apr-07-22 08:00AM
Apr-06-22 08:00AM
Apr-04-22 11:45AM
Mar-31-22 03:10PM
Mar-22-22 08:30AM
Mar-08-22 04:35PM
07:00AM
Mar-01-22 07:00AM
Feb-09-22 07:00AM
Feb-03-22 05:15AM
Feb-02-22 05:38PM
Jan-20-22 09:38PM
Jan-12-22 09:38AM
Jan-10-22 08:21AM
Jan-05-22 07:00AM
Dec-03-21 11:58AM
Nov-11-21 07:00AM
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hannay Michael Charles Ferguso CHIEF PROD & SUPPLY CHAIN OFF Apr 11 '24 Sale 22.49 257 5,780 22,891 Apr 12 04:30 PM Lee Kevin CHIEF EXECUTIVE OFFICER Apr 03 '24 Sale 23.81 3,158 75,192 387,270 Apr 05 04:30 PM Crockett Nigel CHIEF BUSINESS OFFICER Apr 03 '24 Sale 23.81 955 22,739 47,761 Apr 05 04:30 PM Milnes Alistair CHIEF OPERATING OFFICER Apr 03 '24 Sale 23.81 955 22,739 72,241 Apr 05 04:30 PM Skynner Michael CHIEF TECHNOLOGY OFFICER Apr 03 '24 Sale 23.81 955 22,739 94,884 Apr 05 04:30 PM Keen Nicholas CHIEF SCIENTIFIC OFFICER Apr 03 '24 Sale 23.81 790 18,810 62,803 Apr 05 04:30 PM Thompson Travis Alvin CHIEF ACCOUNTING OFFICER Apr 03 '24 Sale 23.81 152 3,619 23,223 Apr 05 04:30 PM Lee Kevin Chief Executive Officer Jan 03 '24 Sale 17.50 8,703 152,302 390,428 Jan 04 06:25 PM Crockett Nigel Chief Business Officer Jan 03 '24 Sale 17.50 2,643 46,252 48,716 Jan 04 06:28 PM Skynner Michael Chief Technology Officer Jan 03 '24 Sale 17.50 2,643 46,252 95,839 Jan 04 06:26 PM Milnes Alistair Chief Operating Officer Jan 03 '24 Sale 17.50 2,643 46,252 73,196 Jan 04 06:27 PM Keen Nicholas Chief Scientific Officer Jan 03 '24 Sale 17.50 2,640 46,200 63,593 Jan 04 06:34 PM Thompson Travis Alvin Chief Accounting Officer Jan 03 '24 Sale 17.50 604 10,570 23,375 Jan 04 06:36 PM Lee Kevin Chief Executive Officer Oct 03 '23 Sale 20.00 1,470 29,400 322,131 Oct 05 05:46 PM Crockett Nigel Chief Business Officer Oct 03 '23 Sale 20.00 442 8,840 29,359 Oct 05 05:48 PM Milnes Alistair Chief Operating Officer Oct 03 '23 Sale 20.00 442 8,840 36,839 Oct 05 05:47 PM Skynner Michael Chief Technology Officer Oct 03 '23 Sale 20.00 442 8,840 70,482 Oct 05 05:46 PM Keen Nicholas Chief Scientific Officer Oct 03 '23 Sale 20.00 272 5,440 38,233 Oct 05 05:49 PM Thompson Travis Alvin Chief Accounting Officer Oct 03 '23 Sale 20.00 54 1,080 7,979 Oct 05 05:50 PM Lee Kevin Chief Executive Officer Jul 03 '23 Sale 25.10 1,498 37,600 323,601 Jul 06 04:51 PM Crockett Nigel Chief Business Officer Jul 03 '23 Sale 25.10 451 11,320 29,801 Jul 06 04:49 PM Skynner Michael Chief Technology Officer Jul 03 '23 Sale 25.10 451 11,320 70,924 Jul 06 04:53 PM Milnes Alistair Chief Operating Officer Jul 03 '23 Sale 25.10 451 11,320 37,281 Jul 06 04:52 PM Keen Nicholas Chief Scientific Officer Jul 03 '23 Sale 25.10 336 8,434 38,505 Jul 06 04:50 PM Thompson Travis Alvin Chief Accounting Officer Jul 03 '23 Sale 25.10 61 1,531 8,033 Jul 06 04:57 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite